Epsilon Healthcare Limited (HDRPF)
OTHER OTC:HDRPF
Want to see HDRPF full AI Analyst Report?
HDRPF Stock Chart & Stats
$0.01
>-$0.01(0.00%)
At close: 4:00 PM EST
$0.01
>-$0.01(0.00%)
Day’s Range― - ―
52-Week Range$0.01 - $0.01
Previous CloseN/A
Volume8.00K
Average Volume (3M)N/A
Market Cap
$5.86M
Enterprise Value$22.09M
Total Cash (Recent Filing)$242.86K
Total Debt (Recent Filing)$14.16M
Price to Earnings (P/E)―
Beta0.04
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding389,104,000
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)4.19
Price to Sales (P/S)1.33
P/FCF Ratio-3.80
Enterprise Value/Market Cap3.77
Enterprise Value/Revenue2.35
Enterprise Value/Gross Profit10.55
Enterprise Value/Ebitda-11.07
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Manufacturing & Regulatory CapabilityOwning cGMP‑compliant extraction and manufacturing gives durable operational control and regulatory alignment. It supports consistent product quality, enables private‑label and B2B contracts, and raises barriers to entry versus pure distribution players, aiding long‑term revenue stability.
Revenue Rebound / Demand RecoveryA ~53% revenue rebound in 2025 signals rising product demand and improving commercial traction across medicinal cannabis and private‑label channels. Sustained top‑line growth can help absorb fixed costs, support incremental investment, and underpin a credible path to scale margins if execution continues.
Improving Unit EconomicsPositive gross profit in 2025 and narrower losses versus prior years indicate improving unit economics and cost control. If sustained, better gross margins provide the basis for operating leverage as revenue grows, increasing the likelihood of transitioning toward sustainable profitability over months.
Bears Say
Weak Cash GenerationNegative operating and free cash flow across all reported years signals persistent cash consumption rather than self‑funding growth. Over a multi‑month horizon this forces dependence on external financing, raising dilution or refinancing risk and constraining investments needed to solidify recent revenue gains into durable margins.
Elevated LeverageDebt-to-equity around 4.7x materially reduces financial flexibility and increases refinancing and covenant pressure. High leverage limits the company's ability to invest organically, heightens vulnerability to interest rate or demand shocks, and shortens the runway to achieve break‑even without fresh capital.
Persistent UnprofitabilityNet margins near -22% indicate the core business is not yet economically self‑sustaining. Continued losses erode equity, necessitate ongoing funding, and mean that structural cost reductions or pricing improvements are required to convert the revenue recovery into durable, profitable operations over the coming months.
Epsilon Healthcare Limited News
HDRPF FAQ
What was Epsilon Healthcare Limited’s price range in the past 12 months?
Epsilon Healthcare Limited lowest stock price was $0.01 and its highest was $0.01 in the past 12 months.
What is Epsilon Healthcare Limited’s market cap?
Epsilon Healthcare Limited’s market cap is $5.86M.
When is Epsilon Healthcare Limited’s upcoming earnings report date?
Epsilon Healthcare Limited’s upcoming earnings report date is Sep 02, 2026 which is in 133 days.
How were Epsilon Healthcare Limited’s earnings last quarter?
Epsilon Healthcare Limited released its earnings results on Feb 27, 2026. The company reported $0.001 earnings per share for the quarter, beating the consensus estimate of N/A by $0.001.
Is Epsilon Healthcare Limited overvalued?
According to Wall Street analysts Epsilon Healthcare Limited’s price is currently Overvalued.
Does Epsilon Healthcare Limited pay dividends?
Epsilon Healthcare Limited does not currently pay dividends.
What is Epsilon Healthcare Limited’s EPS estimate?
Epsilon Healthcare Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Epsilon Healthcare Limited have?
Epsilon Healthcare Limited has 389,104,000 shares outstanding.
What happened to Epsilon Healthcare Limited’s price movement after its last earnings report?
Epsilon Healthcare Limited reported an EPS of $0.001 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Epsilon Healthcare Limited?
Currently, no hedge funds are holding shares in HDRPF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Epsilon Healthcare Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
404.65%
Trailing 12-Months
Asset Growth
84.04%
Trailing 12-Months
Company Description
Epsilon Healthcare Limited
Epsilon Healthcare Limited operates as a healthcare and pharmaceuticals company primarily in Australia and Canada. It engages in the manufacture and distribution of hydroponics equipment, materials, and nutrients; and development and delivery of medicinal cannabis, as well as provides turnkey cannabis cultivation solutions. The company was formerly known as THC Global Group Limited and changed its name to Epsilon Healthcare Limited in February 2021. Epsilon Healthcare Limited was incorporated in 2016 and is based in Sydney, Australia.
Technical Analysis
Vita Life Sciences Limited
―
Little Green Pharma Ltd.
―
Medical Developments International Limited
―
Althea Group Holdings Ltd.
―
IDT Australia Limited
―